{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:30:33Z","timestamp":1790789433354,"version":"4.1.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-11700-0","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T09:40:00Z","timestamp":1759916400000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical outcomes of dolutegravir treatment in people living with HIV in Brazil: protocol for the CODE cohort"],"prefix":"10.1186","volume":"25","author":[{"given":"Carlos","family":"Brites","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estela","family":"Luz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiani","family":"Stelitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabianna","family":"Bahia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus Vin\u00edcius Guimar\u00e3es","family":"de Lacerda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Ramalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra Wagner","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valdez","family":"Madruga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T\u00e2nia","family":"Reuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre Naime","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Dea","family":"Sperhack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica Baumgardt","family":"Bay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T\u00e2mara","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Morejon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Patelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e1bio","family":"Leal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Sprinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Murray-Krezan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Carmody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jess","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Aragon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Chase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Zajdenverg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryn","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Dutra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"11700_CR1","unstructured":"Ministerio de Saude B. Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas para Manejo da Infec\u00e7\u00e3o pelo HIV em Adultos, 2024 [Internet]. 2024. Available from: https:\/\/bvsms.saude.gov.br\/bvs\/publicacoes\/ pcdt_manejo_hiv_adultos_modulo1.pdf. Accessed in 06 Sept 2024."},{"key":"11700_CR2","unstructured":"World Health Organization. WHO recommends dolutegravir as preferred HIV treatment option in all populations. 2023. Available from: https:\/\/www.who.int\/news\/item\/22-07-2019-who-recommends-dolutegravir-as-preferred-hiv-treatment-option-in-all-populations.Accessed. Accessed September 06, 2024."},{"key":"11700_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2147\/CEOR.S439725","volume":"16","author":"S Aprilianti","year":"2024","unstructured":"Aprilianti S, Utami AM, Suwantika AA, Zakiyah N, Azis VI. The cost-effectiveness of dolutegravir in combination with Tenofovir and lamivudine for HIV therapy: A systematic review. Clinicoecon Outcomes Res. 2024;16:25\u201334.","journal-title":"Clinicoecon Outcomes Res"},{"key":"11700_CR4","unstructured":"Wijting I, Wit F, Rokx C. ATHENA National observational HIV cohort. ATHENA National observational HIV cohort."},{"issue":"1","key":"11700_CR5","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.medmal.2020.09.005","volume":"51","author":"A Gaillet","year":"2021","unstructured":"Gaillet A, Calin R, Flandre P, Tubiana R, Valantin M-A, Caumes E, et al. Increased risk of IRIS-associated tuberculosis in HIV-infected patients receiving integrase inhibitors. Infect Dis now. 2021;51(1):90\u20133.","journal-title":"Infect Dis now"},{"key":"11700_CR6","doi-asserted-by":"publisher","unstructured":"Chan CK, Huang SS, Wong KH, Leung CC, Lee MP, Tsang TY et al. No increased risk of tuberculosis-related immune reconstitution inflammatory syndrome with integrase inhibitor-based antiretroviral therapy in people with HIV with profound immunosuppression. HIV Med [Internet]. 2024; Available from: https:\/\/doi.org\/10.1111\/hiv.13695","DOI":"10.1111\/hiv.13695"},{"issue":"2","key":"11700_CR7","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1097\/QAI.0000000000002937","volume":"90","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Hohlfeld A, Namale P, Meintjes G, Maartens G, Engel ME. Risk of immune reconstitution inflammatory syndrome with integrase inhibitors versus other classes of antiretrovirals: A systematic review and meta-analysis of randomized trials. J Acquir Immune Defic Syndr. 2022;90(2):232\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"11700_CR8","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1080\/14787210.2023.2203914","volume":"21","author":"I P\u00e9rez-Valero","year":"2023","unstructured":"P\u00e9rez-Valero I, Corona D, Mart\u00ednez N, L\u00f3pez-Cavanillas M, Lluis C, Luque I. Real-world discontinuations due to neuropsychiatric symptoms in people living with HIV treated with second-generation integrase inhibitors: a systematic review. Expert Rev Anti Infect Ther. 2023;21(6):655\u201365.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"6","key":"11700_CR9","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/COH.0000000000000705","volume":"16","author":"T Senneker","year":"2021","unstructured":"Senneker T, Tseng A. An update on neuropsychiatric adverse effects with second-generation integrase inhibitors and nonnucleoside reverse transcriptase inhibitors. Curr Opin HIV AIDS. 2021;16(6):309\u201320.","journal-title":"Curr Opin HIV AIDS"},{"key":"11700_CR10","unstructured":"Cuzin L, Pugliese P, Katlama C, Dat, \u2019AIDS Study Group. Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohort."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11700-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11700-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11700-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T09:40:06Z","timestamp":1759916406000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-11700-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11700"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11700-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5918947\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]},"assertion":[{"value":"28 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval has been obtained from the IRBs at each participating site, and all participants will provide written informed consent prior to enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not aplicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CB: Research grants: CNPq, GSK, Pfizer, Janssen. All but CNPq grants were awarded to Funda\u00e7\u00e3o Bahiana de Infectologia; Speaker and Advisory board (Gilead, GSK, MSD); SCW: Advisory Boar (ViiV); VM: Speaker (GSK, Gilead, Janssen); ANB: Speaker (Abbvie, Amgen-Bergamo, Astrazeneca, Boehringer Ingelheim, Celltrion, Dr. Reedys, Eurofarma, Gilead, GSK-ViiV, Janssen, Knigth Therapeutics, Moderna, MSD, Pfizer, Procter Gamble, Roche, Sanofi Pasteur, S. C. Johnson Johnson, Takeda, e Wyeth); KP: Has received research grants from the U.S. National Institutes of Health, and U.S. Centers for Disease Control and Prevention. All grants were awarded to the University of New Mexico. RZ: GSK employee; BJ: ViiV Healthcare employee.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1248"}}